Astrazeneca (AZN) Notes Payables (2009 - 2026)

Astrazeneca has reported Notes Payables for 18 years, with the latest figure at -$2.4 billion in Q1 2026.

• On a quarterly basis, Notes Payables fell 154.43% year-over-year to -$2.4 billion in Q1 2026; TTM through Mar 2026 was -$2.4 billion, a 154.43% decrease from a year earlier, with the FY2025 full-year figure at -$13.0 million, up 77.97% from the prior year.
• Notes Payables was -$2.4 billion for Q1 2026 at Astrazeneca, down from -$13.0 million in the prior quarter.
• The five-year high for Notes Payables was -$13.0 million in Q4 2025, with the low at -$2.4 billion in Q1 2026.
• Average Notes Payables over 5 years is -$591.2 million, with a median of -$256.0 million recorded in 2022.
• The sharpest annual moves came in 2024 and 2025: Notes Payables sank 1224.32% in 2024, then surged 77.97% in 2025.
• Over 5 years, Notes Payables stood at -$183.0 million in 2022, then dropped by 10.93% to -$203.0 million in 2023, then jumped by 70.94% to -$59.0 million in 2024, then soared by 77.97% to -$13.0 million in 2025, then tumbled by 18453.85% to -$2.4 billion in 2026.
• The last three Notes Payables figures came in at -$2.4 billion (Q1 2026), -$13.0 million (Q4 2025), and -$1.1 billion (Q3 2025), per Business Quant data.